Tanzania 2027 Compliance Calendar for Medical Device Holders

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The yearly compliance actions of a licence holder in Tanzania can be reduced to four parallel timelines, each independent of the others and none conditional on the rest; each carries its own statutory consequence:

First — the annual retention fee. Article 17(2) of GN 315: the validity of a registration certificate is conditional on payment of the retention fee each year before 31 January (the amount follows the Fees and Charges Regulations in force); Article 17(6) provides that late payment attracts a surcharge. Article 18(g) lists failure to pay the retention fee as a ground for suspending or cancelling the registration. The TMDA issued a notice on 1 October 2026 on the arrangements for the 2027 annual retention fee.

Second — post-market surveillance (PMS) reports. Article 17(3) requires PMS reports; Compendium Part I §5.1(b) and the TMDA public notice of 17 August 2026 express this as biennial submission. The notice lists the nine categories of content the report should cover: quality/safety/performance, adverse events and incidents, complaints, safety signals, field safety corrective actions (FSCA), field safety notices (FSN), recalls, corrective actions and vigilance information. The notice also makes clear that the PMS report does not replace the duty to report adverse events, incidents, safety signals, FSCA and recalls without delay. Articles 18(h) and 18(i) list failure to submit PMS reports, and wilful failure to submit adverse event reports, as grounds for suspension or cancellation.

Third — the premises licence. Article 32(2): a premises licence expires on 30 June each year; Article 35 requires notification of the TMDA within 21 days of any change to the particulars of the licence.

Fourth — renewal of the product registration certificate. Article 17(1): a registration certificate is valid for 5 years; Article 17(4) requires the renewal application to be filed at least 90 days before expiry; Article 17(5) grants a 90-day grace period after expiry. A notification approval is valid for 3 years (Compendium Part I §5.1).

There are also event-triggered obligations: vigilance reporting (Article 42: three bands of 24 hours, 14 days and 30 days), variation applications (G/003), and complaint and supply record-keeping (Articles 39 and 40).

2. Legal basis

RegulationNumberPublication dateProvisions
The Tanzania Food, Drugs and Cosmetics (Control of Medical Devices) Regulations, 2015GN. No. 31531 July 2015Articles 17(1)–(6), 18(g)(h)(i), 32(2), 35, 39, 40, 42
Compendium of Guidelines for Marketing Authorization of Medical Devices, Diagnostics and Laboratory EquipmentNo government gazette number (TMDA guideline document)June 2024Part I §5.1 (validity and three conditions), §3.3.3 (renewal information)
TMDA public notice (post-marketing surveillance reports)No government gazette number (TMDA guideline document)17 August 2026Full text (nine categories of content; does not replace the duty of immediate case reporting)
TMDA public notice (annual retention fee)No government gazette number (TMDA guideline document)1 October 2026Full text (arrangements for 2027)
The Tanzania Medicines and Medical Devices (Fees and Charges) Regulations, 2022No government gazette number (TMDA guideline document)2022Retention fee: registered 200 USD / notified 50 USD (imported tier)

3. Expert insights

Insight 1: the four timelines run in parallel — paying the retention fee does not complete the PMS duty.

Part I §5.1 attaches the validity of the registration simultaneously to three conditions: (a) payment of the annual retention fee; (b) submission of the PMS report; (c) submission of adverse event reports. Article 17(2) and 17(3) are separate provisions, and Article 18(g) and 18(h) are separate grounds. Paying the fee without submitting the PMS report can still cost the certificate. A named owner should be assigned to each timeline, because treating them as one task is how certificates are lost in practice.

Insight 2: 31 January is a deadline to pay before, not during the month.

The wording of Article 17(2) is payment before 31st January. The practical schedule should target completing the payment in early January and obtaining the receipt, leaving margin for banking and confirmation of receipt; late payment generates a surcharge under Article 17(6).

Insight 3: the 30 June premises licence is the timeline most often missed.

The annual expiry in Article 32(2) is independent of the product registration certificates — a valid product certificate does not make the premises lawful. Article 30 is more direct: no business may be conducted without a valid premises licence. For a company holding multiple product certificates, there is only one premises licence, and a missed renewal affects the whole business, so it should carry its own reminder chain.

Insight 4: the starting point of the biennial PMS period needs written confirmation.

The official texts use biennial and biannual interchangeably; the notice of 17 August 2026 uses biennial. The official text does not specify the reference date from which the two-year period is counted (practical estimate). The recommendation is to schedule by the anniversary month of the approval date and to obtain written confirmation of this interpretation from the TMDA. A large portfolio should stagger report months.

Insight 5: one renewal item is easy to trip over — the summary of changes.

Part I §3.3.3(a): the renewal must include a summary of changes made since registration, and it is expressly stated that both approved changes and changes pending approval must be reported. If a company keeps pending changes internal without declaring them, this field of the renewal cannot be completed truthfully. A running change log that distinguishes approved from pending items turns this requirement into a routine export.

Insight 6: the three developments of 2026 will change how 2027 is prepared.

  • The PMS notice of 17 August 2026: report content changes from a general post-market account to nine structured categories; first-time 2027 filers must rebuild their data collection definitions;
  • The MDSAP notice of 24 September 2026: the TMDA became an MDSAP Affiliate member and can obtain MDSAP audit reports and system certification information for desk reviews of quality audits — this affects quality audit evidence preparation, not the registration pathway;
  • The retention fee notice of 1 October 2026: arrangements for the 2027 annual retention fee.

4. Practical recommendations

  1. Build the four timelines into one annual calendar: 31 January (retention fee), the PMS anniversary month, 30 June (premises licence) and 90 days before certificate expiry (renewal).
  2. Collect the nine categories of PMS data continuously, rather than reconstructing them just before submission.
  3. Notify the TMDA within 21 days of any change to the premises licence particulars (name, address, responsible person) (Article 35).
  4. Start the change summary six months before renewal, including pending changes.
  5. Review the TMDA notice board every quarter for annual adjustments to retention fees and PMS requirements.
  6. Fix the three vigilance deadlines (24 hours / 14 days / 30 days) in the quality system SOP and run drills.

5. Verification checklist

  • □ Payment of the annual retention fee before 31 January has been confirmed (imported tier 200 USD / notification 50 USD, subject to the fee regulations in force).
  • □ The PMS report has been scheduled on a biennial basis and covers the nine categories of content.
  • □ The 30 June premises licence expiry date has been confirmed and the renewal scheduled.
  • □ The renewal application has been scheduled for at least 90 days before certificate expiry (with the 90-day grace period as the fallback).
  • □ Renewal information is complete: the change summary (including pending changes), specifications and batch test reports, product information (label artwork / instructions for use), the PMS report, and two commercial packaging samples.
  • □ The three vigilance deadlines (24 hours / 14 days / 30 days) are fixed in the SOP.
  • □ The starting point of the biennial PMS period has been confirmed in writing.
  • □ A quarterly review mechanism for the TMDA notice board has been established (2026-08-17 PMS, 2026-09-24 MDSAP, 2026-10-01 retention fee).

Regulatory information verified as of 29 October 2026. All content cited here has been checked against the TMDA public notices (17 August 2026 and 1 October 2026), the website fee pages and the official published text (GN. No. 315, Articles 17, 18, 30, 32(2), 35, 39, 40 and 42; June 2024 Compendium, Part I §3.3.3 and §5.1); the review is repeated whenever the regulations are updated.

  • Tanzania local resources: GRZAN can coordinate licensed local responsible persons (LRP) and distributor resources covering online submission, sample delivery, quality audit support and port clearance.
  • Service capabilities: classification determination, registration and notification pathway selection, technical documentation (CSDT/STED) preparation and localization, GMDN and grouping strategy, clinical evidence organization, software and AI device submissions, change management, vigilance and PMS reporting, annual retention fee and renewal management.
  • Contact: info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail